GlobeNewswire Inc.··SanofiSanofi's Lunsekimig Clears Key Phase 2 Hurdles in Asthma and Sinus Disease
Sanofi's bispecific antibody lunsekimig met primary endpoints in phase 2 asthma and chronic rhinosinusitis studies, though atopic dermatitis trial missed targets.
SNYchronic rhinosinusitis with nasal polypsatopic dermatitis